title: Selecting an appropriate and reimbursed anti-osteoporotic treatment option: a practical tool in the Belgian setting.
abstract: Osteoporosis is a highly prevalent and often undertreated disease in the elderly. Osteoporosis-related fractures are associated with significant morbidity and mortality. Anti-osteoporotic drugs are only reimbursed by the Belgian government if strict conditions are fulfilled. The aim of this paper was to create a practical tool to guide the physician and other health care professionals to make an appropriate choice. Two flowcharts, based on Belgian reimbursement criteria and literature review were developed. Both tools provide an overview of the reimbursed pharmacological agents in the management of osteoporosis in male and female subjects.
authors.affiliation: Pharmacy Dept., University Hospitals Leuven, Leuven, Belgium. veerle.grootaert@uzleuven.be
authors.forename: V
authors.initials: V
authors.lastname: Grootaert
authors.forename: J
authors.initials: J
authors.lastname: De Keulenaer
authors.forename: S
authors.initials: S
authors.lastname: Boonen
authors.forename: A
authors.initials: A
authors.lastname: Sermon
authors.forename: I
authors.initials: I
authors.lastname: Spriet
authors.forename: L
authors.initials: L
authors.lastname: Willems
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001530:Belgium; D019091:Critical Pathways; D003661:Decision Support Techniques; D003663:Decision Trees; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000150:complications / Q000175:diagnosis* / Q000628:therapy*; D012051:Reimbursement Mechanisms